KBC Group
CSTL icon

KBC Group’s Castle Biosciences CSTL Stock Holding History

KBC Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$907K Buy
+36,932
New +$1.21M ﹤0.01% 732

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's CSTL Position: Q1 2026 in Review

KBC Group opened a new position in Castle Biosciences (CSTL) in Q1 2026: 36,932 shares worth $907K. The stake represents ﹤0.01% of the portfolio and ranks #732 among its holdings.

186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • KBC Group held 36,932 shares of Castle Biosciences worth $907K as of Q1 2026.
  • Castle Biosciences was a new KBC Group position in Q1 2026.
  • Castle Biosciences made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #732 holding.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.